A six month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six month open label extension) to assess the safety and efficacy of 700microg and 350microg dexamehtasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusio

• Conditions: Macular edema following Central Retinal Vein occlusione or Branch Retinal Vein Occlusion; MedDRA version: 6.1Level: PTClassification code 10038907

• Registration Number: EUCTR2004-002502-29-IT
• Lead Sponsor: ALLERGA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-06-27
• Last Update Posted: 23 May 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified